Skip to main content
[Preprint]. 2020 Dec 22:2020.12.20.20248572. [Version 1] doi: 10.1101/2020.12.20.20248572

Figure 4. Cross-phenotype analysis and COVID-19 patient transcriptomics reveals a role for DPP9 in severe COVID-19.

Figure 4.

(A) Lung eQTL data from GTEx shows rs12610495 “G” allele is associated with reduced expression of DPP9.

(B) Regional Miami colocalization plot demonstrates the DPP9 locus impacts both idiopathic pulmonary fibrosis and risk of severe COVID-19.

(C) A significant positive correlation for effect size of SNPs in the DPP9 locus on idiopathic pulmonary fibrosis and risk of severe COVID-19.

(D) Model of how DPP9 may affect idiopathic pulmonary fibrosis and risk of severe COVID-19.

(E) DPP9 expression in peripheral blood is significantly higher in COVID-19 patients compared to healthy and bacteria-infected patients. The p values were calculated using the Wilcoxon rank-sum test.

(F) COVID-19 patients demonstrate significantly higher DPP9 expression compared to healthy controls during early (days 1–10), middle (days 11–20) and late (21+ days) stages of SARS-CoV-2 infection. The p values were calculated using the Wilcoxon rank-sum test.

(G) DPP9 demonstrates increased expression during recovery from COVID-19. A total of 11 patients were measured sequentially at enrollment (day 0), day 7, and day 14. The colored dash line connects measurements from the same patient across time points. P value was calculated using Friedman test.

(H) Decreased symptom severity scores of COVID-19 patients over time. The eleven subjects in G were assessed for symptom severity at day 0, 7 and 14. The colored dash line connects measurements from the same patient across time points. P value was calculated using Friedman test.